With a market capitalization of ₹ 2565 crores, Neuland Laboratories is a small-cap company that manufactures active pharmaceutical ingredients. It is an end-to-end solution provider for the pharmaceutical industry’s chemistry needs.
Ace investor Vijay Kedia recently increased his stake in Neuland Laboratories through his company Kedia Securities Pvt Ltd (KSPL). Vijay Kedia is one of the most successful investors in India with a net worth of over ₹ 800 crores.
According to the shareholding pattern for the latest quarter (January to March 2023), KSPL holds 1,50,000 shares or a 1.17% stake in the company. This indicates an increase of 0.16 % as compared to 1,30,000 shares or a 1.01% stake in the company as of the September to December quarter of 2022.
Neuland Laboratories shares were trading at ₹ 2035.55 apiece at 12:32 PM. It has a dividend yield of 0.25% and an ideal debt-to-equity ratio of 0.24. Its shares were trading at a price-to-earnings ratio of 25.46 which is lower than the industry P/E of 27.68, indicating that the stock is undervalued as compared to its peers. It has a return on equity of 7.85%.
The shareholding pattern of the company shows that its promoters hold a 36.14% stake in it, retail investors hold 44.73%, foreign institutions hold 18.14% and mutual funds hold 0.99%.
The company’s revenue increased by 13.86% to ₹ 269.25 crores for the quarter ending December 31, 2022, compared to ₹ 236.47 crores in the corresponding quarter last year. Its net profit increased by 136.09% to ₹ 30.55 crores in the December quarter as compared to ₹ 12.94 crores in the same quarter last year.
Written by Simran Bafna
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
